Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Strasse 4, D-64287 Darmstadt, Germany.
Biomolecules. 2019 Jan 21;9(1):35. doi: 10.3390/biom9010035.
The FK506-binding protein 51 (FKBP51) has emerged as a key regulator of endocrine stress responses in mammals and as a potential therapeutic target for stress-related disorders (depression, post-traumatic stress disorder), metabolic disorders (obesity and diabetes) and chronic pain. Recently, FKBP51 has been implicated in several cellular pathways and numerous interacting protein partners have been reported. However, no consensus on the underlying molecular mechanisms has yet emerged. Here, we review the protein interaction partners reported for FKBP51, the proposed pathways involved, their relevance to FKBP51's physiological function(s), the interplay with other FKBPs, and implications for the development of FKBP51-directed drugs.
FK506 结合蛋白 51（FKBP51）已成为哺乳动物内分泌应激反应的关键调节剂，也是与应激相关疾病（抑郁症、创伤后应激障碍）、代谢疾病（肥胖和糖尿病）和慢性疼痛的潜在治疗靶点。最近，FKBP51 已涉及多种细胞途径，并且已经报道了许多相互作用的蛋白伙伴。然而，尚未就潜在的分子机制达成共识。在这里，我们回顾了已报道的 FKBP51 的蛋白相互作用伙伴、所涉及的提议途径、它们与 FKBP51 的生理功能的相关性、与其他 FKBP 的相互作用以及对开发 FKBP51 靶向药物的影响。
